Activity of interferon-α in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
Activity of interferon-α in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
复制标题
DOI：
10.1023/a:1008384506227
复制
发表时间：
2000-03-01
影响因子：
50.5
通讯作者：
Coiffier, B
中科院分区：
文献类型：
--
作者：
Armitage, JO;Coiffier, B
长期以来，已知干扰素-α是滤泡性淋巴瘤[1-3]和皮肤T细胞淋巴瘤[4-6]以及多种其他恶性肿瘤（包括毛细胞白血病、慢性髓性白血病、多发性骨髓瘤、恶性黑色素瘤和肾细胞癌[7-10]）中的活性剂。然而，人们普遍认为干扰素-α在弥漫性侵袭性非霍奇金淋巴瘤患者的治疗中不是一种有用的药物。尽管早期的干扰素试验显示复发的侵袭性淋巴瘤有适度的应答率[11-13]。在观察了下面描述的患者后，我们对弥漫性侵袭性淋巴瘤患者中干扰素-a的活性产生了兴趣。这促使我们对世界各地的肿瘤学家进行调查，试图找出类似的患者。
Interferon-a has long been known to be an active agent in follicular lymphoma [1-3] and cutaneous T-cell lymphoma [4-6] in addition to a variety of other malignancies including hairy cell leukemia, chronic myeloid leukemia, multiple myeloma, malignant melanoma, and renal cell carcinoma [7-10]. However, it has been widely believed that interferon-a is not a useful agent in the management of patients with diffuse aggressive non-Hodgkin's lymphoma. This is despite the fact that early trials with interferon-a showed a modest response rate in aggressive lymphomas in relapse [11-13]. We became interested in the activity of interferon-a in patients with diffuse aggressive lymphoma after observing the patient described below. This led us to carry out a survey of oncologists worldwide in an attempt to identify similar patients.